Neuropathic pain affects approximately 7-10% of the population, causing chronic burning, shooting, or electric-shock sensations that significantly impact quality of life.
When traditional treatments like medications and physical therapy haven’t provided adequate relief, transcranial magnetic stimulation (TMS) offers an evidence-based alternative.
At Complete Mind Care of PA, with locations in Villanova and Horsham, our experienced team of over 20 board-certified providers offers advanced neuromodulation treatments for neuropathic pain as part of comprehensive care.
Our leadership team brings extensive experience from building a successful 35-location TMS practice, giving us deep expertise in neuromodulation treatments. We serve more than 4,500 active patients across our Horsham and Villanova locations with extended hours (7 AM – 8 PM weekdays) to accommodate your schedule.
We understand that living with neuropathic pain means managing not just physical discomfort, but the frustration of trying multiple treatments, sleep disruption, mood challenges, and reduced functional capacity. Remission is our mission, and we’re committed to exploring evidence-based approaches that may help you reclaim quality of life.
Neuropathic pain is defined as pain arising from a lesion or disease affecting the somatosensory nervous system. Unlike nociceptive pain (which results from tissue damage), neuropathic pain stems from damage or dysfunction in the nerves themselves, causing abnormal pain signals even in the absence of tissue injury.
Diabetic Peripheral Neuropathy: The most common form of neuropathic pain, affecting approximately 50% of people with diabetes. High blood glucose levels damage small nerve fibers, particularly in the feet and hands, causing burning pain, numbness, tingling, and heightened sensitivity to touch.
Post-Herpetic Neuralgia: Persistent pain following shingles (herpes zoster) infection. The virus damages nerve fibers, causing burning, stabbing, or electric-shock sensations that can persist for months or years after the rash heals. Most common in older adults and those with weakened immune systems.
Chemotherapy-Induced Peripheral Neuropathy: Nerve damage from cancer treatments, particularly platinum-based chemotherapy, taxanes, and vinca alkaloids. Causes numbness, tingling, burning pain, and loss of sensation in hands and feet that can persist long after treatment completion.
Post-Surgical Neuropathic Pain: Nerve damage from surgical procedures, including mastectomy, thoracotomy, amputation, and spinal surgery. Can result in persistent pain at surgical sites even after tissue healing is complete.
Spinal Cord Injury: Damage to the spinal cord can cause central neuropathic pain characterized by burning, squeezing, or shooting sensations below the level of injury. Affects 40-60% of individuals with spinal cord injury.
Radiculopathy: Nerve root compression from herniated discs, spinal stenosis, or degenerative disc disease causing radiating pain, numbness, and weakness along the affected nerve distribution (sciatica, cervical radiculopathy).
Traumatic Nerve Injury: Direct nerve damage from accidents, falls, or penetrating injuries causing pain in the distribution of the injured nerve. May include complex regional pain syndrome (CRPS) or neuroma formation.
Post-Stroke Pain: Central post-stroke pain syndrome affecting 8-12% of stroke survivors, typically developing weeks to months after stroke. Causes burning, aching pain usually on the side of the body opposite the stroke.
Trigeminal Neuralgia: Severe facial pain from trigeminal nerve dysfunction, causing sudden, severe electric-shock-like episodes triggered by touch, eating, or talking.
Neuropathic pain often presents with distinctive qualities that differentiate it from other pain types:
Pain Qualities: Burning, shooting, stabbing, electric-shock sensations, or pins-and-needles feelings. Pain may be constant or intermittent and often worsens at night.
Abnormal Sensations: Allodynia (pain from normally non-painful stimuli like light touch or clothing), hyperalgesia (exaggerated pain response to painful stimuli), and paresthesias (spontaneous tingling or prickling).
Sensory Changes: Numbness, reduced sensation, or paradoxical combination of numbness and pain in the same area. Loss of protective sensation increases risk of injury and ulceration.
Functional Impact: Difficulty walking, impaired manual dexterity, reduced balance, and increased fall risk. Sleep disruption is common as pain often intensifies at night.
Psychological Burden: Depression, anxiety, social withdrawal, and reduced quality of life are common companions to chronic neuropathic pain.
Standard neuropathic pain management typically includes FDA-approved medications (gabapentin, pregabalin, duloxetine), tricyclic antidepressants, topical agents (lidocaine, capsaicin), physical therapy, occupational therapy, psychological support, and management of underlying conditions (glucose control in diabetes). However, these treatments provide adequate relief in only 30-50% of patients, and many experience intolerable side effects. This has led clinicians to investigate complementary approaches like brain stimulation.
Important Note: TMS is not FDA-approved for treating neuropathic pain. At Complete Mind Care of PA, we offer TMS for neuropathic pain relief as an advanced treatment option based on substantial research evidence. This treatment is provided on a cash-pay basis and should be viewed as complementary to standard pain management, not a replacement for comprehensive care.
Research has focused primarily on the primary motor cortex (M1) as the target region. High-frequency stimulation (typically 10 Hz) of the motor cortex contralateral to the painful area has shown the most consistent pain reduction across multiple neuropathic pain conditions. The motor cortex has extensive connections to pain processing networks, and modulating its activity can influence descending pain control pathways and alter activity in connected regions including the thalamus, insula, and anterior cingulate cortex.
Some studies have also explored the dorsolateral prefrontal cortex (DLPFC) as an alternative or adjunctive target, particularly when depression co-occurs with neuropathic pain. However, motor cortex stimulation has shown superior pain-relieving effects in most studies.
Neuropathic pain involves dysfunction in the nervous system’s pain processing, characterized by central sensitization, altered cortical organization, and impaired descending pain modulation. Neuroimaging and neurophysiological studies show individuals with neuropathic pain have:
Maladaptive cortical reorganization: Changes in motor cortex representation, with areas corresponding to painful regions showing altered excitability and expanded or contracted representation
Hyperactive pain networks: Excessive activity in pain perception areas including the insula, anterior cingulate cortex, and somatosensory cortex
Impaired descending inhibition: Reduced ability of the brain to naturally suppress pain signals through descending pathways from the brainstem
Altered network connectivity: Disrupted communication between regions responsible for pain processing, attention, emotion, and motor control
Neuroplastic changes: Persistent alterations in neural circuits that maintain chronic pain even after initial tissue or nerve damage has healed
TMS delivers magnetic pulses through a coil placed on the scalp, creating electrical currents that modulate neural activity. High-frequency motor cortex stimulation works through multiple mechanisms:
Restoration of cortical organization: TMS can normalize the maladaptive reorganization of motor cortex representation that occurs with chronic pain. Studies show TMS restores normal motor cortex excitability patterns that are disrupted in neuropathic pain conditions.
Enhanced descending pain inhibition: Stimulating the motor cortex activates descending pain modulation pathways originating in the periaqueductal gray and rostral ventromedial medulla. This enhances the brain’s natural ability to suppress pain signals from peripheral nerves.
Modulation of pain network activity: TMS influences activity in interconnected networks including the thalamus, brainstem, insula, and anterior cingulate cortex—all regions critically involved in neuropathic pain processing. Functional imaging shows TMS normalizes overactivity in these regions.
Neurotransmitter modulation: TMS increases release of endogenous opioids and modulates levels of glutamate, GABA, and other neurotransmitters involved in pain regulation. This alters the balance between excitatory and inhibitory signaling in pain circuits.
Neuroplastic changes: Repeated TMS sessions induce lasting changes in synaptic strength and neural connectivity, potentially reversing the maladaptive plasticity that maintains chronic neuropathic pain.
Reduced central sensitization: By modulating activity in pain processing regions, TMS may help reduce the heightened pain sensitivity and abnormal pain responses characteristic of central sensitization.
Improved functional connectivity: TMS can restore more normal patterns of communication between brain regions involved in pain, attention, and emotional processing, helping to break cycles of pain and suffering.
The evidence base for TMS in neuropathic pain has grown substantially, with multiple randomized controlled trials and meta-analyses demonstrating efficacy:
A landmark multicenter randomized controlled trial published in Brain Stimulation studied 153 patients with peripheral neuropathic pain across four centers in France. Patients were randomized to receive motor cortex TMS, prefrontal cortex TMS, or sham stimulation (10 Hz, 3000 pulses per session, 15 sessions over 22 weeks). Motor cortex TMS reduced pain intensity significantly compared to sham stimulation, with effects maintained through the 25-week study period. Prefrontal cortex stimulation was not superior to sham. The treatment showed an excellent safety profile with headache being the most common side effect.
A comprehensive systematic review and meta-analysis examining TMS for neuropathic pain confirmed that high-frequency (10 Hz) motor cortex stimulation produces significant pain reduction with moderate to large effect sizes. The analysis found particularly strong evidence for efficacy in spinal cord injury, diabetic peripheral neuropathy, and post-herpetic neuralgia.
Studies specifically examining diabetic peripheral neuropathy have shown motor cortex TMS produces significant improvements in pain intensity, nerve conduction parameters, and functional capacity. Research in Egypt demonstrated high-frequency motor cortex TMS (10 Hz, five consecutive days) reduced pain scores significantly in both insulin-dependent and non-insulin-dependent diabetic patients with resistant neuropathic pain, with effects lasting through 3-month follow-up.
Research on post-herpetic neuralgia shows motor cortex TMS (10 Hz, 80% motor threshold, 10 sessions) produces significant pain reduction and quality of life improvements lasting up to 3 months post-treatment. A randomized trial comparing different frequencies demonstrated 10 Hz stimulation produced superior outcomes to both 5 Hz stimulation and sham.
An expert consensus panel from the International Neuromodulation Society and North American Neuromodulation Society granted Level A (Extremely Recommendable) and Level IB (Strongly Recommended for Clinical Implementation) recommendations supporting neuronavigation-guided high-frequency motor cortex TMS for appropriate neuropathic pain indications including post-stroke central pain and trigeminal neuralgia. They noted conditions with more peripheral anatomical origins like post-traumatic peripheral neuropathy showed less favorable responses.
Meta-analyses examining TMS across all neuropathic pain conditions show approximately 30-50% of patients achieve clinically meaningful pain reduction (≥30% reduction), with some studies reporting even higher response rates. Effects are most pronounced for central neuropathic pain conditions (post-stroke pain, spinal cord injury pain) compared to purely peripheral neuropathies, though significant benefits have been demonstrated across multiple neuropathic pain types.
Treatment begins with thorough assessment by our board-certified psychiatrists or psychiatric nurse practitioners. We’ll review:
We’ll conduct standardized pain assessments and determine the optimal TMS protocol for your presentation. We’ll also perform a motor threshold test to calibrate the TMS device to your individual neurophysiology.
TMS protocols for neuropathic pain typically involve:
Target: Primary motor cortex (M1) contralateral to the painful side, or left motor cortex for bilateral pain
Frequency: High-frequency stimulation at 10 Hz (most evidence-supported protocol)
Intensity: 80-120% of your resting motor threshold
Pulses: 2000-3000 pulses per session
Induction phase: Daily sessions Monday through Friday for 2 weeks (10 sessions)
Maintenance phase: Weekly sessions for 4-8 weeks in extended protocols
Session duration: 20-40 minutes depending on the protocol
Our team will design a personalized protocol based on current research evidence, your specific pain condition, and treatment goals.
You’ll sit comfortably in a recliner while the TMS coil is positioned over your scalp targeting the motor cortex. The treatment produces clicking sounds and creates a tapping sensation on your scalp. Most patients tolerate this well. You’ll remain awake and alert throughout treatment—many patients read, listen to music, or simply relax. You can drive yourself to and from appointments and resume normal activities immediately.
We use standardized assessments to track changes in:
Regular check-ins help us understand how treatment is affecting your day-to-day life and adjust our approach as needed.
If benefits occur, they typically emerge gradually over the course of treatment. Some patients notice subtle improvements in pain intensity or sleep quality within the first 1-2 weeks. More substantial improvements in pain, function, and quality of life generally become apparent after 4-6 weeks of treatment (15-20 sessions).
Based on clinical trial data, pain relief often reaches maximum benefit around weeks 8-12, with some patients experiencing sustained benefits lasting 3-6 months after completing treatment. Maintenance sessions may help extend the duration of benefits, though optimal maintenance schedules have not been definitively established.
TMS for neuropathic pain may be appropriate if you:
Research suggests TMS may be most effective for:
FDA status: TMS for neuropathic pain is investigational and not FDA-approved. Evidence is substantial, particularly for motor cortex stimulation in specific pain conditions, but ongoing research is needed to optimize protocols and understand who benefits most.
Not a replacement for comprehensive care: TMS should complement, not replace, your existing pain management including medications, physical therapy, occupational therapy, psychological support, and management of underlying conditions (such as glucose control in diabetic neuropathy). Continue all treatments recommended by your pain specialist or neurologist.
Individual response variability: Research shows meaningful pain reduction in approximately 30-50% of patients, with some experiencing even greater benefit. However, response varies between individuals. Factors like pain condition type, pain duration, baseline severity, comorbid depression, and central versus peripheral pain origin may influence outcomes. Central neuropathic pain conditions (post-stroke, spinal cord injury) generally show more robust responses than purely peripheral neuropathies.
Pain condition matters: The strongest evidence supports TMS for specific conditions including diabetic neuropathy, post-herpetic neuralgia, spinal cord injury pain, and post-stroke pain. Evidence for other neuropathic pain conditions is more limited but emerging.
Time and financial commitment: A full protocol involves 10-20+ sessions over 8-16 weeks. This requires significant scheduling flexibility and financial resources. Our extended hours help accommodate work schedules.
Multidisciplinary approach works best: TMS appears most effective when combined with other evidence-based treatments including physical therapy, psychological support, appropriate medications, and management of underlying conditions.
We recognize that neuropathic pain is often invisible to others, and many patients have experienced frustration with treatments that haven’t worked or side effects that weren’t tolerable. Our team provides validating, patient-centered care that respects your experience and treatment preferences.
We understand that chronic neuropathic pain affects every aspect of life—work capacity, relationships, mental health, sleep, and sense of self. Our goal is not just pain reduction, but helping you reclaim function and quality of life despite pain.
Our comfortable, private treatment rooms offer a calm, supportive environment. We work collaboratively with your existing healthcare providers—pain specialists, neurologists, endocrinologists, oncologists, and primary care physicians—to ensure comprehensive care. All TMS sessions are supervised by our trained clinical staff with immediate access to our board-certified psychiatric providers who have extensive experience in neuromodulation and chronic pain treatment.
Because TMS for neuropathic pain is not FDA-approved for this indication, this treatment is not covered by insurance and is provided on a cash-pay basis. We provide transparent pricing during your consultation so you can make informed decisions about whether this investment aligns with your healthcare priorities.
Given the significant financial commitment and investigational nature of this treatment, we encourage careful consideration and discussion with your medical team before proceeding. Our team can provide documentation for any reimbursement requests you wish to pursue with your insurance carrier, though coverage is unlikely.
Research shows strongest evidence for motor cortex TMS in:
Central neuropathic pain conditions (originating in the brain or spinal cord) generally show more robust responses than purely peripheral neuropathies, though significant benefits have been demonstrated across multiple pain types.
TMS is non-invasive and reversible, making it a lower-risk option to consider before invasive surgical procedures. However, the decision depends on your specific condition, pain severity, functional limitations, and previous treatment responses. Discuss with your pain specialist and our team to determine the most appropriate sequencing of treatments for your situation. TMS and surgical neuromodulation can also sometimes be used complementarily.
Disclaimer: TMS for neuropathic pain is an investigational treatment approach and is not FDA-approved for this indication. Individual results vary significantly. This treatment should be viewed as complementary to, not replacement for, standard neuropathic pain care. This information is for educational purposes and does not constitute medical advice. Consult with qualified healthcare providers specializing in pain management and neurology to determine if TMS is appropriate for your situation.
Conditions Treated
721 Dresher Rd # 1100, Horsham, PA 19044
721 Dresher Rd # 1100, Horsham, PA 19044
Complete Mind Care was founded on the premise of providing full mental health support delivered by a team of expert professionals, in the comfort of a world-class facility local to you—so you can build a foundation for lasting recovery close to home. Plus 40+ additional insurance carriers accepted.
Don’t see your insurance listed? Call our office at 215-607-7250 or 215-918-7939 to verify coverage.
